Isogenica is attending BIO Digital 2021

Jun 7, 2021

Isogenica is excited to announce its attendance at BIO Digital 2021.

Isogenica’s Director of Business Development Dr David Mead, and Associate Director of Marketing, Dr Mandeep Sehmi will be attending the BIO International Convention Digital 2021 June 10-11 & 14-18.

BIO Digital provides an excellent opportunity to expand and update our network.

Isogenica specialises in single-domain biotherapeutics. In collaboration with biopharmaceutical partners over the last decade, Isogenica has developed a deep pipeline including two clinical assets (Phase I and II respectively) and numerous partnered discovery and pre-clinical stage programs with cutting edge global biotech.

The Isogenica antibody library is entirely synthetic, providing a key advantage that VHH are generated to specific epitopes which are difficult to target using conventional immunisation methods. VHH represent an attractive construct for incorporation in CAR-T and T-cell engaging therapeutic format with carefully designed affinities, valencies and specificities enabling refined tumour cell targeting and modes of action.

Isogenica’s focus for BIO 2021 is to demonstrate our developing pipeline and outline for in vivo proof of concept data which will be generated by this year.

Using our proprietary platform we discover therapeutic antibodies that meet the highest standards of quality and developability. Isogenica has the in-house capability and expertise to efficiently undertake and manage all of your discovery & development activities from programme start to development.

If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”

Contact

Mandeep Sehmi,
Business Development

T +44 1799 533 680

E mandeep.sehmi@isogenica.com

Contact us